MDXH vs SEER
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
MDXH exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -9.30, indicating negative shareholder equity. While the company maintains a strong gross margin (64.55%) and positive revenue growth (~19%), these are completely offset by catastrophic ROE (-2440%) and a consistent track record of missing earnings estimates (0/4 beats in the last year). The technical trend is purely bearish, and the lack of a valid Altman Z-Score combined with poor liquidity ratios suggests a high risk of insolvency.
SEER exhibits severe fundamental weakness, highlighted by a critical Piotroski F-Score of 1/9, indicating poor financial health and operational deterioration. Despite a strong current ratio suggesting a remaining cash runway, the company suffers from an abysmal operating margin of -413.83% and stagnant revenue growth of 5%. The long-term price trajectory is catastrophic (-96% over 5 years), and recent insider selling by the CEO and President further signals a lack of confidence in a near-term turnaround.
Compare Another Pair
Related Comparisons
MDXH vs SEER: Head-to-Head Comparison
This page compares MDxHealth SA (MDXH) and Seer, Inc. (SEER) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.